Abstract |
Although OATP1B1 is not expressed in the kidney, polymorphisms in SLCO1B1 have been associated with methotrexate clearance or toxicity. This unexpected pharmacogenetic association may reflect remote communication between liver and kidney transporters. This study confirms the pharmacogenetic association with methotrexate toxicity in adult patients with hematological malignancies. Using a targeted urinary metabolomics approach, we identified 38 and 34 metabolites which were differentially excreted between wildtype and carriers of the c.388A>G or c.521T>C variant alleles, respectively, half of them being associated with methotrexate toxicity. These metabolites mainly consisted of fatty acid derivatives and microbiota catabolites, including glycine conjugates and other uremic toxins, all known OATs substrates. These results suggest that dysfunction of a transporter affects the excretion profile of endogenous or exogenous substrates, possibly through metabolite-mediated interactions involving other transport systems, even in distant organs. This opens the way for better comprehension of complex pharmacokinetics and transporter-mediated drug-drug or nutrient-drug interactions.
|
Authors | David Martinez, Kienana Muhrez, Jean-Baptiste Woillard, Aline Berthelot, Emmanuel Gyan, Sylvain Choquet, Christian R Andrès, Pierre Marquet, Chantal Barin-Le Guellec |
Journal | Clinical pharmacology and therapeutics
(Clin Pharmacol Ther)
Vol. 104
Issue 4
Pg. 687-698
(10 2018)
ISSN: 1532-6535 [Electronic] United States |
PMID | 29285751
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Observational Study)
|
Copyright | © 2017 American Society for Clinical Pharmacology and Therapeutics. |
Chemical References |
- Antimetabolites, Antineoplastic
- Liver-Specific Organic Anion Transporter 1
- Organic Anion Transport Protein 1
- Organic Anion Transporters, Sodium-Independent
- SLCO1B1 protein, human
- organic anion transport protein 3
- Methotrexate
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antimetabolites, Antineoplastic
(adverse effects, pharmacokinetics)
- Female
- Gas Chromatography-Mass Spectrometry
- Genotype
- Hematologic Neoplasms
(drug therapy, urine)
- Humans
- Kidney
(metabolism)
- Liver
(metabolism)
- Liver-Specific Organic Anion Transporter 1
(genetics, metabolism)
- Male
- Metabolomics
(methods)
- Methotrexate
(adverse effects, pharmacokinetics)
- Middle Aged
- Organic Anion Transport Protein 1
(metabolism)
- Organic Anion Transporters, Sodium-Independent
(metabolism)
- Pharmacogenetics
(methods)
- Pharmacogenomic Variants
- Polymorphism, Single Nucleotide
- Prospective Studies
- Renal Elimination
- Urinalysis
- Young Adult
|